| Primary |
| Blood Product Transfusion |
25.0% |
| Coagulation Test Abnormal |
25.0% |
| Coagulopathy |
25.0% |
| Haemorrhage |
25.0% |
|
| Product Quality Issue |
21.4% |
| Transfusion-related Acute Lung Injury |
14.3% |
| Accidental Exposure |
7.1% |
| Drug Ineffective For Unapproved Indication |
7.1% |
| Exposure To Contaminated Device |
7.1% |
| Pharmaceutical Product Complaint |
7.1% |
| Product Contamination Physical |
7.1% |
| Product Sterility Lacking |
7.1% |
| Transfusion Reaction |
7.1% |
| Transfusion-related Circulatory Overload |
7.1% |
| Tremor |
7.1% |
|
| Secondary |
| Product Used For Unknown Indication |
60.2% |
| Drug Use For Unknown Indication |
7.9% |
| Factor Viii Deficiency |
4.3% |
| Operative Haemorrhage |
4.3% |
| Aortic Dissection |
3.5% |
| Dental Implantation |
3.1% |
| Consumptive Coagulopathy |
2.4% |
| Hypovolaemia |
2.4% |
| Panel-reactive Antibody |
1.6% |
| Panel-reactive Antibody Increased |
1.6% |
| Shock Haemorrhagic |
1.6% |
| Transfusion |
1.6% |
| Transplant Rejection |
1.2% |
| Coronary Artery Bypass |
0.8% |
| Endoscopy |
0.8% |
| Haemolytic Uraemic Syndrome |
0.8% |
| Multiple Sclerosis |
0.8% |
| Ceruloplasmin Decreased |
0.4% |
| Off Label Use |
0.4% |
| Schizophrenia |
0.4% |
|
| Renal Failure Acute |
22.7% |
| Transfusion-related Acute Lung Injury |
13.6% |
| Incision Site Infection |
9.1% |
| Hepatitis C |
6.8% |
| Death |
4.5% |
| Drug Ineffective |
4.5% |
| Hypothermia |
4.5% |
| Pharmaceutical Product Complaint |
4.5% |
| Renal Impairment |
4.5% |
| Anxiety |
2.3% |
| Drug Hypersensitivity |
2.3% |
| Drug Interaction |
2.3% |
| Haemolysis |
2.3% |
| Hepatitis A Antibody Positive |
2.3% |
| Hiv Infection |
2.3% |
| Hypotension |
2.3% |
| Influenza |
2.3% |
| Oedema Peripheral |
2.3% |
| Respiratory Gas Exchange Disorder |
2.3% |
| Resuscitation |
2.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
48.1% |
| Coronary Artery Bypass |
9.0% |
| Pulmonary Oedema |
5.8% |
| Aortic Valve Replacement |
5.4% |
| Drug Use For Unknown Indication |
4.1% |
| Prophylaxis |
2.7% |
| Sepsis |
2.7% |
| Hypertension |
2.5% |
| Mitral Valve Replacement |
2.4% |
| Electrolyte Substitution Therapy |
2.4% |
| Cardiogenic Shock |
2.2% |
| Multiple Myeloma |
1.7% |
| Anaemia |
1.6% |
| Premedication |
1.6% |
| Coagulopathy |
1.4% |
| Mitral Valve Repair |
1.4% |
| Escherichia Sepsis |
1.3% |
| Tricuspid Valve Repair |
1.3% |
| Aortic Surgery |
1.2% |
| Post Procedural Haemorrhage |
1.2% |
|
| Injury |
12.9% |
| Unevaluable Event |
10.2% |
| Pain |
9.4% |
| Anxiety |
7.9% |
| Anhedonia |
6.9% |
| Fear |
6.7% |
| Renal Impairment |
5.7% |
| Emotional Distress |
5.2% |
| Renal Failure Acute |
5.2% |
| Renal Failure |
5.0% |
| Depression |
4.7% |
| Renal Injury |
4.0% |
| Platelet Count Decreased |
2.7% |
| Stress |
2.7% |
| Pulmonary Oedema |
2.5% |
| Multi-organ Failure |
2.0% |
| Death |
1.7% |
| Thrombocytopenia |
1.7% |
| White Blood Cell Count Increased |
1.5% |
| Cardio-respiratory Arrest |
1.2% |
|
